Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Operating Expenses (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Operating Expenses data on record, last reported at $34.2 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 20.34% year-over-year to $34.2 million; the TTM value through Dec 2025 reached $151.2 million, down 2.6%, while the annual FY2025 figure was $151.2 million, 2.6% down from the prior year.
  • Operating Expenses reached $34.2 million in Q4 2025 per CCCC's latest filing, down from $45.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $45.6 million in Q3 2025 and bottomed at $27.9 million in Q1 2021.
  • Average Operating Expenses over 5 years is $37.7 million, with a median of $39.0 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: surged 55.38% in 2021, then decreased 20.34% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $35.3 million in 2021, then rose by 16.45% to $41.1 million in 2022, then fell by 1.12% to $40.7 million in 2023, then rose by 5.4% to $42.9 million in 2024, then decreased by 20.34% to $34.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $34.2 million in Q4 2025, $45.6 million in Q3 2025, and $35.0 million in Q2 2025.